All In Biotech

Drug Trial Radar · NCT01163253

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Jun 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,867

Actual

Start

Sep 2010

Primary completion

Jun 2016

Study completion Jun 2016

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 15, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.

Conditions

  • Psoriasis

Interventions

  • CP-690,550Drug

    5 mg oral BID

  • CP-690,550Drug

    10 mg oral BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
  2. Number of Adverse Events (AEs) by SeverityTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
  3. Number of Participants With Laboratory AbnormalitiesTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
  4. Change From Baseline in Hemoglobin Level at Month 1Time frame: Baseline, Month 1
  5. Change From Baseline in Hemoglobin Level at Month 3Time frame: Baseline, Month 3
  6. Change From Baseline in Hemoglobin Level at Month 6Time frame: Baseline, Month 6
  7. Change From Baseline in Hemoglobin Level at Month 12Time frame: Baseline, Month 12
  8. Change From Baseline in Hemoglobin Level at Month 24Time frame: Baseline, Month 24
  9. Change From Baseline in Hemoglobin Level at Month 36Time frame: Baseline, Month 36
  10. Change From Baseline in Hemoglobin Level at Month 48Time frame: Baseline, Month 48
  11. Change From Baseline in Lymphocyte and Neutrophil Count at Month 1Time frame: Baseline, Month 1
  12. Change From Baseline in Lymphocyte and Neutrophil Count at Month 3Time frame: Baseline, Month 3
  13. Change From Baseline in Lymphocyte and Neutrophil Count at Month 6Time frame: Baseline, Month 6
  14. Change From Baseline in Lymphocyte and Neutrophil Count at Month 12Time frame: Baseline, Month 12
  15. Change From Baseline in Lymphocyte and Neutrophil Count at Month 24Time frame: Baseline, Month 24
  16. Change From Baseline in Lymphocyte and Neutrophil Count at Month 36Time frame: Baseline, Month 36
  17. Change From Baseline in Lymphocyte and Neutrophil Count at Month 48Time frame: Baseline, Month 48
  18. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 1Time frame: Baseline, Month 1
  19. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 3Time frame: Baseline, Month 3
  20. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 6Time frame: Baseline, Month 6
  21. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 12Time frame: Baseline, Month 12
  22. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 24Time frame: Baseline, Month 24
  23. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 36Time frame: Baseline, Month 36
  24. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 48Time frame: Baseline, Month 48
  25. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 1Time frame: Baseline, Month 1
  26. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 3Time frame: Baseline, Month 3
  27. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 6Time frame: Baseline, Month 6
  28. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 12Time frame: Baseline, Month 12
  29. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 24Time frame: Baseline, Month 24
  30. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 36Time frame: Baseline, Month 36
  31. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 48Time frame: Baseline, Month 48
  32. Number of Participants With Clinically Significant Change From Baseline in Physical ExaminationTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
  33. Number of Participants With Vital Sign AbnormalitiesTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
  34. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 1Time frame: Baseline, Month 1
  35. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 3Time frame: Baseline, Month 3
  36. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 6Time frame: Baseline, Month 6
  37. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 12Time frame: Baseline, Month 12
  38. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 24Time frame: Baseline, Month 24
  39. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 36Time frame: Baseline, Month 36
  40. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 48Time frame: Baseline, Month 48
  41. Change From Baseline in Heart Rate at Month 1Time frame: Baseline, Month 1
  42. Change From Baseline in Heart Rate at Month 3Time frame: Baseline, Month 3
  43. Change From Baseline in Heart Rate at Month 6Time frame: Baseline, Month 6
  44. Change From Baseline in Heart Rate at Month 12Time frame: Baseline, Month 12
  45. Change From Baseline in Heart Rate at Month 24Time frame: Baseline, Month 24
  46. Change From Baseline in Heart Rate at Month 36Time frame: Baseline, Month 36
  47. Change From Baseline in Heart Rate at Month 48Time frame: Baseline, Month 48
  48. Number of Participants With Electrocardiogram (ECG) AbnormalitiesTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
  49. Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 6Time frame: Baseline, Month 6
  50. Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 12Time frame: Baseline, Month 12
  51. Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 24Time frame: Baseline, Month 24
  52. Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 36Time frame: Baseline, Month 36
  53. Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 48Time frame: Baseline, Month 48
  54. Number of Participants With Adjudicated Cardiovascular EventsTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
  55. Number of Participants With Malignancy EventsTime frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)

Locations

323 sites in 36 countries. Site status is shown where the registry gives one.

  • Radiant Research, Inc.

    Birmingham, Alabama

  • UAB Dermatology

    Birmingham, Alabama

  • Horizon Research Group, Inc.

    Mobile, Alabama

  • Radiant Research, Inc.

    Tucson, Arizona

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • Bakersfield Dermatology and Skin Cancer Medical Group

    Bakersfield, California

  • Associates In Research, Inc.

    Fresno, California

  • University of California Irvine

    Irvine, California

  • Dermatology Research Associates

    Los Angeles, California

  • Dermatology Specialists, Inc.

    Oceanside, California

  • MedDerm Associates

    San Diego, California

  • UCSD Dermatology

    San Diego, California

  • University of California San Diego

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • Clinical Science Institute

    Santa Monica, California

  • Healthcare Partners Medical Group

    Torrance, California

  • Cherry Creek Research, Inc.

    Denver, Colorado

  • The Savin Center, P.C.

    New Haven, Connecticut

  • New England Research Associates, LLC

    Trumbull, Connecticut

  • Florida Academic Dermatology Center

    Coral Gables, Florida

  • North Florida Dermatology Associates, PA

    Jacksonville, Florida

  • International Dermatology Research, Inc.

    Miami, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Park Avenue Dermatology, PA

    Orange Park, Florida

  • Leavitt Medical Associates of Florida dba Ameriderm Research

    Ormond Beach, Florida

  • Miami Research Associates, Inc.

    South Miami, Florida

  • Olympian Clinical Research

    Tampa, Florida

  • Atlanta Dermatology, Vein & Research Center, P.C.

    Alpharetta, Georgia

  • Advanced Medical Research, Inc.

    Atlanta, Georgia

  • MedaPhase Inc.

    Newnan, Georgia

  • Altman Dermatology Associates

    Arlington Heights, Illinois

  • Schaumburg Dermatology

    Schaumburg, Illinois

  • NorthShore University Health System - Division of Dermatology

    Skokie, Illinois

  • Springfield Clinic

    Springfield, Illinois

  • Dundee Dermatology

    West Dundee, Illinois

  • Deaconess Clinic Downtown Research Institute

    Evansville, Indiana

  • Hudson Dermatology

    Evansville, Indiana

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • DermResearch, PLLC

    Louisville, Kentucky

  • Tufts Medical Center

    Boston, Massachusetts

Showing 40 of 323 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.